FIELD: medicine.
SUBSTANCE: offered is medical device adapted for local application or introduction in hollow tubes and containing therapeutic dose of N-{5-[4-(4-methylpiperazinomethyl) benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidinamine or its salt, crystal form with possible release thereof, its application for prevention or reduction of dysfunction caused by approach to vessels and related method of treatment (prevention). Particularly offered is method of restenosis treatment or prevention inpatients suffering from diabetes. It is detected that local introduction of M-{5-[4-(4-methylpiperazinomethyl) benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidinamine or its pharmaceutically acceptable salt or crystal form under declared method provides unexpectedly high stability of compound within 45 days compared to its activity value when introduced as free form.
EFFECT: provides high stability of compound.
5 cl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITIONS | 2004 |
|
RU2363497C2 |
LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR STIMULATORS | 2008 |
|
RU2510654C2 |
METHOD OF PREVENTION OR TREATMENT OF REDUCTION OF ACCESS FOR VESSEL HEMODIALYSIS AND DEVICE FOR ITS REALISATION AND OTHER VASCULAR GRAFTS | 2002 |
|
RU2345719C2 |
LOCAL DELIVERY OF COMBINATION OF ADENOSINE A2A RECEPTOR AGONISTS/PHOSPHODIESTERASE INHIBITOR IN VESSELS TO RELIEVE MYOCARDIAL INVOLVEMENT SEVERITY | 2011 |
|
RU2565403C2 |
COMPOSITION COMPRISING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRILYL)-2-PYRIDINEAMINE AND CHEMOTHERAPEURIC AGENT | 2002 |
|
RU2318517C2 |
4-FLUORO-N-INDANE-2-YLBENZAMIDE AND ITS USING AS PHARMACEUTICAL AGENT | 2002 |
|
RU2308946C2 |
STENT WITH DOUBLE DRUG RELEASE | 2010 |
|
RU2552086C2 |
CANCER MEDICAL TREATMENT | 2005 |
|
RU2325906C2 |
COMBINATION AND METHOD FOR PROPHYLAXIS OF BREAST CANCER | 2002 |
|
RU2322981C2 |
APPLICATION OF RAPAMYCIN DERIVATIVE | 2013 |
|
RU2659725C2 |
Authors
Dates
2008-12-20—Published
2003-02-27—Filed